Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Justera Health Ltd C.VTAL

Alternate Symbol(s):  SCRSF

Justera Health Ltd. is a Canadian company focused on health and wellness. It offers personalized healthcare services and solutions, such as IV Vitamin Therapy, premium nutritional supplements through its Naturevan Nutrition brand, a full 360-degree wellness and spa experience through Juillet Wellness that provides registered massage therapy, acupuncture, and new retail stores in Vancouver. Its Concierge Medical business provides discreet and personalized concierge healthcare services, including IV Vitamin Therapy. Its services include Screenpro Security, Justera Health Product, Naturevan, Juillet Wellness, and TRINITI Corporation. It is also specialized in providing efficient COVID-19 testing and same-day test results through its Canadian labs. It offers two convenient methods to test: in clinic testing or mobile at home testing. It is a distributor of TonyMoly skin care products in Canada. It provides a full-service wellness center, providing a range of beauty and wellness services.


CSE:VTAL - Post by User

Comment by bohemian62on Mar 10, 2022 9:16pm
62 Views
Post# 34505183

RE:RE:RE:RE:RE:RE:Was Lena The Most Qualified Candidate?

RE:RE:RE:RE:RE:RE:Was Lena The Most Qualified Candidate?So have all the other covid testing stocks . That is a fact . Don't blame Lena .

Feb 8, 2022, Our indicative theme on Covid-19 Testing Stocks – which includes companies that produce or carry out tests for Covid-19 infections - has underperformed considerably thus far in 2022, declining by about 14% year-to-date, compared to the S&P 500 which has declined about 6% over the same period. While testing demand surged through the holidays and in early January, as daily U.S. Covid-19 cases peaked at over 1 million, they have shown a declining trend recently, falling to an average of 322k as of last week. This could lead to more muted demand for testing. Moreover, there are concerns about long-term testing demand for a couple of reasons. For one, therapeutic options for Covid-19 are getting better and this could make people less inclined to get tested as soon as they develop symptoms. Secondly, the virus could also get milder, with the now dominant omicron strain itself apparently having a lower rate of severe disease. Separately, considering that testing stocks have provided solid returns over the last two years (about 47% over 2020 and 22% in 2021), investors are likely reducing exposure to the theme.
<< Previous
Bullboard Posts
Next >>